ASH2025: My top 6 myeloma abstracts
Published:
This late-breaking abstract is possibly the best of the whole congress. Nearly 600 relapsed and refractory myeloma (RRMM) patients on this study were randomised to receive either teclistamab (Tecvayli®) and daratumumab (Darzalex®) or standard of care therapy (daratumumab with dexamethasone and either bortezomib (Velcade®) (DVD) or pomalidomide (Imnovid®) (DPD). At three years, 83.4% of patients were alive and in remission in the teclistamab arm compared with 29.7% of patients on the standard therapy arm.
Sign up and become a member of the Myeloma UK HCP Hub
Access exclusive content like this and join in the conversation.
Already have an account?